OpenURL Connection Search

Select item for more details and to access through your institution.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Published in:
2016
By:
- Berdeja, Jesus;
- Jagannath, Sundar;
- Zonder, Jeffrey;
- Badros, Ashraf;
- Kaufman, Jonathan L.;
- Manges, Robert;
- Gupta, Manish;
- Tendolkar, Amol;
- Lynch, Mark;
- Bleickardt, Eric;
- Paliwal, Prashni;
- Vij, Ravi
Publication type:
journal article
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Published in:
International Journal of Hematology, 2022, v. 115, n. 2, p. 222, doi. 10.1007/s12185-021-03241-4
By:
- Nowakowski, Grzegorz S.;
- Willenbacher, Wolfgang;
- Greil, Richard;
- Larsen, Thomas S.;
- Patel, Krish;
- Jäger, Ulrich;
- Manges, Robert F.;
- Trümper, Lorenz;
- Everaus, Hele;
- Kalakonda, Nagesh;
- Brown, Peter;
- Jørgensen, Judit Meszaros;
- Cunningham, David;
- Dell'Aringa, Justine;
- Fox, Brian;
- Rubio, Neus Domper;
- Kilavuz, Nurgul;
- Casadebaig, Marie-Laure;
- Manzke, Oliver;
- Munoz, Javier
Publication type:
Article
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Published in:
American Journal of Hematology, 2017, v. 92, n. 5, p. 460, doi. 10.1002/ajh.24687
By:
- Berenson, James;
- Manges, Robert;
- Badarinath, Suprith;
- Cartmell, Alan;
- McIntyre, Kristi;
- Lyons, Roger;
- Harb, Wael;
- Mohamed, Hesham;
- Nourbakhsh, Ali;
- Rifkin, Robert
Publication type:
Article
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Published in:
British Journal of Haematology, 2013, v. 161, n. 3, p. 357, doi. 10.1111/bjh.12266
By:
- Voorhees, Peter M.;
- Manges, Robert F.;
- Sonneveld, Pieter;
- Jagannath, Sundar;
- Somlo, George;
- Krishnan, Amrita;
- Lentzsch, Suzanne;
- Frank, Richard C.;
- Zweegman, Sonja;
- Wijermans, Pierre W.;
- Orlowski, Robert Z.;
- Kranenburg, Britte;
- Hall, Brett;
- Casneuf, Tineke;
- Qin, Xiang;
- Velde, Helgi;
- Xie, Hong;
- Thomas, Sheeba K.
Publication type:
Article

Found: 4

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.